RepliCel Files Notice of Arbitration against Shiseido Company to Resolve its License Agreement Dispute Regarding its Androgenetic Alopecia Cell Therapy October 18, 2021
RepliCel Life Sciences Appoints One of Japan’s Foremost Regenerative Medicine Industry Business Leaders as Strategic Advisor October 12, 2021
RepliCel and University of Victoria Collaboration Leads to Bioengineering Innovations, Funding, and Patents September 16, 2021
RepliCel Applies for Manufacturing Approval for its Collagen and Tissue Regeneration Cell Therapies July 7, 2021
RepliCel Launches Preparations for Second Skin Rejuvenation and Tendon Regeneration Clinical Studies May 19, 2021
RepliCel Launches the Next Stage of a Research Project with the University of British Columbia to Build World-Class Hair Follicle Cell Data Map May 11, 2021
RepliCel Announces Appointment of Leading Sports Medicine Expert as Orthopedics Clinical Advisor (Japan) May 3, 2021
RepliCel Presents Its Technology Development and Commercialization Plans for Japan at Kanagawa Regenerative Medicine Industry Conference February 18, 2021
Healthcare Roundup – Sesen price target raised on prospects for bladder cancer therapy; Sundial makes $22M investment in cannabis edibles company Indiva February 16, 2021 Life Science
Healthcare Roundup – G1 Therapeutics jumps 16.9% as trilaciclib wins FDA approval; Bionano Genomics shares hit all-time high, spiking nearly 23% February 12, 2021 Life Science
Healthcare Roundup – Generex announces receipt of $2M for its COVID-19 vaccine development; I-Mab’s cancer therapy greenlighted in China for phase 1 trial February 10, 2021 Life Science
